aTyr Pharma (ATYR) News Today $5.14 -0.34 (-6.20%) Closing price 06/17/2025 04:00 PM EasternExtended Trading$5.16 +0.02 (+0.29%) As of 05:47 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ATYR Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 Time Period With 70% ownership, aTyr Pharma, Inc. (NASDAQ:ATYR) boasts of strong institutional backingJune 17 at 10:09 AM | finance.yahoo.com91,224 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Bought by Bank of America Corp DEBank of America Corp DE bought a new position in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor bought 91,224 shares of the company's stock, valued at approximatelyJune 14, 2025 | marketbeat.comCantor Fitzgerald Estimates Atyr PHARMA FY2026 EarningsJune 12, 2025 | americanbankingnews.comCantor Fitzgerald Predicts Atyr PHARMA FY2026 EarningsAtyr PHARMA INC (NASDAQ:ATYR - Free Report) - Equities researchers at Cantor Fitzgerald issued their FY2026 earnings per share estimates for Atyr PHARMA in a research report issued on Monday, June 9th. Cantor Fitzgerald analyst P. Agrawal anticipates that the company will earn ($0.78) per share fJune 11, 2025 | marketbeat.comAtyr PHARMA (NASDAQ:ATYR) Trading 6.1% Higher - Here's What HappenedAtyr PHARMA (NASDAQ:ATYR) Trading 6.1% Higher - Should You Buy?June 10, 2025 | marketbeat.comaTyr Pharma Stock Price HistoryJune 6, 2025 | investing.comaTyr Pharma reports positive interim results for SSc-ILD treatmentJune 5, 2025 | investing.comAtyr PHARMA (NASDAQ:ATYR) Sees Unusually-High Trading Volume - Here's What HappenedAtyr PHARMA (NASDAQ:ATYR) Sees Large Volume Increase - Time to Buy?June 4, 2025 | marketbeat.comAtyr PHARMA's (ATYR) Buy Rating Reiterated at HC WainwrightHC Wainwright restated a "buy" rating and issued a $35.00 target price on shares of Atyr PHARMA in a research note on Wednesday.June 4, 2025 | marketbeat.comaTyr Pharma Announces Findings from Interim Analysis of Ongoing Phase 2 EFZO-CONNECT™ Study of Efzofitimod in Systemic Sclerosis-Related Interstitial Lung Disease (SSc-ILD)June 4, 2025 | globenewswire.comMillennium Management LLC Takes $1.33 Million Position in Atyr PHARMA INC (NASDAQ:ATYR)Millennium Management LLC acquired a new stake in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 367,989 shares of the company's stock, valued at approximately $1,332,000. MilleJune 4, 2025 | marketbeat.com182,625 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Bought by Northern Trust CorpNorthern Trust Corp purchased a new position in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor purchased 182,625 shares of the company's stock, valued at apJune 1, 2025 | marketbeat.comAtyr PHARMA INC (NASDAQ:ATYR) Receives Consensus Recommendation of "Buy" from BrokeragesAtyr PHARMA INC (NASDAQ:ATYR - Get Free Report) has received an average rating of "Buy" from the seven analysts that are covering the company, Marketbeat reports. Six research analysts have rated the stock with a buy rating and one has issued a strong buy rating on the company. The average 12 moMay 30, 2025 | marketbeat.comHigh Growth Tech Stocks in the US to Watch This May 2025May 27, 2025 | finance.yahoo.comJane Street Group LLC Invests $720,000 in Atyr PHARMA INC (NASDAQ:ATYR)Jane Street Group LLC bought a new position in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the 4th quarter, according to its most recent 13F filing with the SEC. The fund bought 199,006 shares of the company's stock, valued at approximately $720,000. Jane Street Group LLC owned 0.24% oMay 27, 2025 | marketbeat.comaTyr Pharma’s SWOT analysis: biotech firm’s stock poised for potential breakthroughMay 26, 2025 | investing.comWoodline Partners LP Invests $6.09 Million in Atyr PHARMA INC (NASDAQ:ATYR)Woodline Partners LP purchased a new position in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund purchased 1,683,000 shares of the company's stock, valuedMay 26, 2025 | marketbeat.comHC Wainwright Reaffirms Buy Rating for Atyr PHARMA (NASDAQ:ATYR)HC Wainwright reaffirmed a "buy" rating and issued a $35.00 price objective on shares of Atyr PHARMA in a report on Monday.May 21, 2025 | marketbeat.comOMERS ADMINISTRATION Corp Takes Position in Atyr PHARMA INC (NASDAQ:ATYR)OMERS ADMINISTRATION Corp bought a new stake in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund bought 138,000 shares of the company's stock, valued at approximaMay 21, 2025 | marketbeat.comaTyr Pharma to Present at Upcoming Investor ConferencesMay 20, 2025 | globenewswire.comTang Capital Management LLC Invests $2.43 Million in Atyr PHARMA INC (NASDAQ:ATYR)Tang Capital Management LLC purchased a new stake in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 671,134 shares of the company's stockMay 20, 2025 | marketbeat.comPoint72 Asset Management L.P. Purchases New Stake in Atyr PHARMA INC (NASDAQ:ATYR)Point72 Asset Management L.P. purchased a new stake in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 4,883,197 shares of the company's stock, valued at apprMay 20, 2025 | marketbeat.comaTyr Pharma Presents Three Posters on Efzofitimod at the American Thoracic Society (ATS) 2025 International ConferenceMay 19, 2025 | globenewswire.comDimensional Fund Advisors LP Makes New $881,000 Investment in Atyr PHARMA INC (NASDAQ:ATYR)Dimensional Fund Advisors LP purchased a new position in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 243,369 shares of the companMay 18, 2025 | marketbeat.comaTyr Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 16, 2025 | globenewswire.comOctagon Capital Advisors LP Makes New $3.26 Million Investment in Atyr PHARMA INC (NASDAQ:ATYR)Octagon Capital Advisors LP bought a new position in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor bought 900,000 shares of the company's stock, valued at approximately $3,258,000.May 15, 2025 | marketbeat.comaTyr Pharma, Inc.: aTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary FibrosisMay 14, 2025 | finanznachrichten.deaTyr Pharma Advances ATYR0101 to IND Candidate Stage for Pulmonary FibrosisMay 14, 2025 | globenewswire.comIntegral Health Asset Management LLC Buys New Stake in Atyr PHARMA INC (NASDAQ:ATYR)Integral Health Asset Management LLC acquired a new position in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 375,000 shares of the company's stock, valued at approximateMay 14, 2025 | marketbeat.comJ. Goldman & Co LP Buys New Shares in Atyr PHARMA INC (NASDAQ:ATYR)J. Goldman & Co LP bought a new stake in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 300,131 shares of the company's stock, valued at approximately $1,086,000. J.May 14, 2025 | marketbeat.comQ3 Earnings Forecast for Atyr PHARMA Issued By HC WainwrightAtyr PHARMA INC (NASDAQ:ATYR - Free Report) - HC Wainwright cut their Q3 2025 earnings per share estimates for Atyr PHARMA in a report issued on Thursday, May 8th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings of ($0.19) per share for the quarter, down fromMay 13, 2025 | marketbeat.comLeerink Partnrs Estimates Atyr PHARMA Q2 EarningsAtyr PHARMA INC (NASDAQ:ATYR - Free Report) - Equities research analysts at Leerink Partnrs issued their Q2 2025 EPS estimates for Atyr PHARMA in a report issued on Wednesday, May 7th. Leerink Partnrs analyst F. Khurshid expects that the company will earn ($0.17) per share for the quarter. LeerinMay 13, 2025 | marketbeat.comBarclays PLC Acquires New Position in Atyr PHARMA INC (NASDAQ:ATYR)Barclays PLC bought a new position in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 159,407 shares of the company's stock, valued at approximately $577,000. Barclays PLCMay 11, 2025 | marketbeat.comIs aTyr Pharma, Inc. (ATYR) the Low Risk High Reward Stock Set to Triple by 2030?May 10, 2025 | insidermonkey.comAlyeska Investment Group L.P. Invests $4.63 Million in Atyr PHARMA INC (NASDAQ:ATYR)Alyeska Investment Group L.P. acquired a new stake in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,278,441 shares of the company's stock, valued atMay 8, 2025 | marketbeat.comaTyr Pharma Announces First Quarter 2025 Results and Provides Corporate UpdateMay 7, 2025 | globenewswire.comWells Fargo & Company MN Invests $383,000 in Atyr PHARMA INC (NASDAQ:ATYR)Wells Fargo & Company MN purchased a new position in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 105,769 shares of the company's stock, valued at aMay 6, 2025 | marketbeat.comAtyr PHARMA INC (NASDAQ:ATYR) Short Interest Up 20.6% in AprilAtyr PHARMA INC (NASDAQ:ATYR - Get Free Report) was the target of a large increase in short interest in April. As of April 15th, there was short interest totalling 10,030,000 shares, an increase of 20.6% from the March 31st total of 8,320,000 shares. Approximately 11.7% of the company's stock are sold short. Based on an average daily trading volume, of 1,390,000 shares, the short-interest ratio is currently 7.2 days.May 5, 2025 | marketbeat.comFY2026 EPS Estimates for Atyr PHARMA Decreased by AnalystAtyr PHARMA INC (NASDAQ:ATYR - Free Report) - Equities research analysts at HC Wainwright reduced their FY2026 earnings per share (EPS) estimates for Atyr PHARMA in a report issued on Tuesday, April 29th. HC Wainwright analyst J. Pantginis now forecasts that the company will post earnings per shaMay 4, 2025 | marketbeat.comAlly Bridge Group NY LLC Invests $2.53 Million in Atyr PHARMA INC (NASDAQ:ATYR)Ally Bridge Group NY LLC acquired a new stake in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 699,730 shares of the company's stock, valued at approximately $2,533,000. Atyr PHARMA makMay 4, 2025 | marketbeat.com248,000 Shares in Atyr PHARMA INC (NASDAQ:ATYR) Acquired by 683 Capital Management LLC683 Capital Management LLC bought a new stake in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund bought 248,000 shares of the company's stock, valued atMay 4, 2025 | marketbeat.comAdage Capital Partners GP L.L.C. Buys New Shares in Atyr PHARMA INC (NASDAQ:ATYR)Adage Capital Partners GP L.L.C. purchased a new position in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 1,000,000 shares of the company's stock, vMay 2, 2025 | marketbeat.comJPMorgan Chase & Co. Boosts Stake in Atyr PHARMA INC (NASDAQ:ATYR)JPMorgan Chase & Co. raised its position in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) by 467.8% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 178,532 shares of the company's stock after buMay 2, 2025 | marketbeat.comAtyr PHARMA (ATYR) Projected to Post Earnings on ThursdayAtyr PHARMA (NASDAQ:ATYR) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-atyr-pharma-inc-stock-1/)April 30, 2025 | marketbeat.comGeode Capital Management LLC Buys Shares of 891,407 Atyr PHARMA INC (NASDAQ:ATYR)Geode Capital Management LLC bought a new stake in shares of Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor bought 891,407 shares of the company'sApril 30, 2025 | marketbeat.comaTyr Pharma Presents Preclinical Data for NRP2-Targeting Antibody ATYR2810 at the American Association for Cancer Research (AACR) Annual Meeting 2025April 29, 2025 | globenewswire.comRenaissance Technologies LLC Makes New $2.08 Million Investment in Atyr PHARMA INC (NASDAQ:ATYR)Renaissance Technologies LLC acquired a new stake in Atyr PHARMA INC (NASDAQ:ATYR - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 574,455 shares of the company's stock, valued at aApril 28, 2025 | marketbeat.comAtyr PHARMA (ATYR) to Release Quarterly Earnings on ThursdayAtyr PHARMA (NASDAQ:ATYR) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-atyr-pharma-inc-stock-1/)April 26, 2025 | marketbeat.comPulmonary Sarcoidosis Market Set to Experience Significant Growth Through 2032, Driven by Emerging Novel Therapies | DelveInsightApril 24, 2025 | theglobeandmail.comCantor maintains Overweight on aTyr Pharma stock ahead of trialsApril 22, 2025 | investing.com Get aTyr Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter. Email Address ATYR Media Mentions By Week ATYR Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ATYR News Sentiment▼1.180.56▲Average Medical News Sentiment ATYR News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ATYR Articles This Week▼73▲ATYR Articles Average Week Get aTyr Pharma News Delivered to You Automatically Sign up to receive the latest news and ratings for ATYR and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies IDEAYA Biosciences News Schrödinger News Indivior News Galapagos News Apogee Therapeutics News Beam Therapeutics News Immunocore News Tarsus Pharmaceuticals News Bausch Health Companies News Disc Medicine News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ATYR) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredWhat 99% of investors are missing about Chinese AIChinese AI chatbot DeepSeek's release put the spotlight on AI and turned the tech world on its head. But 99...Weiss Ratings | SponsoredThe one deadline Elon can't afford to miss...For years, Elon Musk made headlines for blowing past deadlines — so often that investors coined a nickname for...Brownstone Research | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredTrump wipes out trillions overnight…Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored72 Hours Until Musk’s $34 Trillion AI Network BeginsIn just 72 hours, Elon Musk is expected to flip the switch on Tesla’s autonomous network in Austin, Texas. ...The Oxford Club | SponsoredSorry about the swear wordWhat a huge few months for Bitcoin. First, Bitcoin hit $100,000… Then, Donald Trump pledged to create an...Manward Press | SponsoredPresident Trump Could Soon Unlock Trillions in New WealthIf you think America is broke, think again. These "reserve accounts" are worth trillions... And according t...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding aTyr Pharma, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share aTyr Pharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy ATYR Stock Free ATYR Stock Alerts